Axon reflex

Axonics to Participate in the SUFU 2023 Winter Meeting

Retrieved on: 
Tuesday, March 7, 2023
Medical Supplies, Medical Devices, Health, Health Technology, General Health, Biotechnology, Role, Physician, Effectiveness, Nocturia, Overactive bladder, Patient, Fecal incontinence, Incontinence, Urinary retention, SUFU, Quality of life, SNM, Society, Winter Meeting, Durability, OAB, Pharmaceutical industry, Axon reflex

In addition, data highlighting the experience of patients with Axonics SNM therapy will include three poster presentations:

Key Points: 
  • In addition, data highlighting the experience of patients with Axonics SNM therapy will include three poster presentations:
    The Role of Age in the Effectiveness of SNM for OAB – presented by Ayman Mahdy, M.D., Ph.D.
  • Effectiveness of the Axonics SNM System in Improving Sleep Quality of Life for Patients Suffering with Nocturia – presented by Michael Kennelly, M.D.
  • Efficacy and Durability of the Predictive Programming Algorithm of the Axonics SNM System – presented by Ryan Krlin, M.D.
  • “The SUFU 2023 Winter Meeting provides an opportunity for physicians to learn more about Axonics SNM therapy and the durable symptom relief patients are experiencing, directly from their peers,” said Karen Noblett, M.D., chief medical officer of Axonics.

Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System

Retrieved on: 
Thursday, September 8, 2022
Medical Devices, FDA, Hospitals, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Fecal incontinence, Incontinence, University of Alberta, University, INS, SNM, Department, Urinary incontinence, Health Canada, Deloitte Technology Fast 500, Quality of life, F15, Financial Times, Nasdaq, FDA, News, MRI, FRCS, U.S. FDA, Woman, SUI, Overactive bladder, Longevity, Adoption, Patient, Pharmaceutical industry, Medical device, Medical imaging, Axon reflex

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in Canada with the Axonics F15, the companys newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in Canada with the Axonics F15, the companys newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.
  • The Axonics F15 received regulatory approval from Health Canada following U.S. FDA approval.
  • The approval of the Axonics recharge-free system is welcome news for patients in Canada suffering from bladder and bowel dysfunction, said Gary J.
  • Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy.